1. World Health Organisation. Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics. 2017. https://www.who.int/medicines/publications/global-priority-list-antibiotic-resistant-bacteria/en/. Accessed 18 June 2019.
2. U.S. Food and Drug Administration. FDA approves new antibacterial drug. 2017.
3. Eurpean Medicines Agency (EMA). Zerbaxa: EPAR - Product Information. 2018.
4. Sakoulas G. Meropenem/vaborbactam approved in U.S. for Complicated Urinary Tract Infection. NEJM Group; 2018. https://www.jwatch.org/na45133/2017/10/18/meropenem-vaborbactam-approved-us-complicated-urinary. Accessed 12 Sept 2019.
5. Alexander EL, Loutit J, Tumbarello M, Wunderink R, Felton T, Daikos G, et al. Carbapenem-resistant Enterobacteriaceae infections: results from a retrospective series and implications for the design of prospective clinical trials. Open Forum Infect Dis. 2017;4(2). https://doi.org/10.1093/ofid/ofx063.